Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 neg MSH6 W628* |
| Therapy | Nivolumab |
| Indication/Tumor Type | glioblastoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 neg MSH6 W628* | glioblastoma | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a clinical case study, Opdivo (nivolumab) treatment resulted in a 60% reduction of tumor size and durable clinical response that was still ongoing after 10 months in a pediatric patient with refractory glioblastoma that was CD274 (PD-L1) negative, and was also diagnosed with constitutional mismatch repair-deficiency (CMMRD) syndrome due to biallelic MSH6 W628* mutation (PMID: 30104292). | 30104292 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (30104292) | Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency. | Full reference... |